LLY's "Patent CLIFF" is INCY's bonus -- CEO John Lechleiter told CNBC on Tuesday, but added the company is engaged in other ways to revive growth next year.
Lilly was cultivating new lines of medicines and existing markets.
"We saw the patent cliff coming as recently as the middle of the last decade and began to invest in our pipeline," the CEO said, giving management time to respond with new drug trials. He said Lilly has about seven in various stages of testing -- INCY is one of them!
Guidance is expected to resume growth after 2014 -- again when INCY's products pour out of the pipeline.